Ilancheran Arunachalam

Arunachalam Ilancheran

  • Associate Professor, Department of Obstetrics & Gynaecology
  • Senior Consultant, Department of Obstetrics & Gynaecology, National University Hospital
Academic Qualifications
  • MBBS, National University of Singapore, Singapore
  • MMed (O&G), National University of Singapore, Singapore
  • MD, National University of Singapore, Singapore
  • FRCOG, Royal College of Obstetrics & Gynaecology, United Kingdom
  • FAMS, Academy of Medicine, Singapore
Research Interest(s)
  • Cervix Cancer
  • Ovarian Cancer
Recent Publications
  • 1. Ngoi, N. Y. L., Heong, V., Lee, X. W., Huang, Y. Q., Thian, Y. L., Choo, B. A., . . . Tan, D. S. P. (2018). Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. Gynecologic Oncology Reports, 24, 1-5. doi:10.1016/j.gore.2018.01.009.
  • 2. Koh V, Choo BA, Lee KM, Tan TH, Low JHJ, Ng SYJ, Ilancheran A, Shen L, Tang J. 2017 Jan. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients. Brachytherapy. 16(1):126-132. doi: 10.1016/j.brachy.2016.09.009.
  • 3. Dashraath P, Lim LM, Huang Z, Ilancheran A. 2016 Nov. Parasitic leiomyoma. American Journal of Obstetrics and Gynecology. 215(5): 665. doi: 10.1016/j.ajog.2016.07.017.
  • 4. Ilancheran A. 2016 May. Neoadjuvant chemotherapy in cervical cancer in pregnancy. Best practice & research. Best Pract Res Clin Obstet Gynaecol. 33:102-7. doi: 10.1016/j.bpobgyn.2015.10.008.
  • 5. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, Kitchener H, Fong KL, Bouchard C, Money DM, Ilancheran A, Cruickshank ME, Levin MJ, Chatterjee A, Stapleton JT, Martens M, Quint W, David MP, Meric D, Hardt K, Descamps D, Geeraerts B, Struyf F, Dubin G; VIVIANE Study Group. 2014 Dec. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 384(9961):2213-27. doi: 10.1016/S0140-6736(14)60920-X.